Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial. [electronic resource]
Producer: 20170623Description: 6234-6241 p. digitalISSN:- 1552-5783
- Angiogenesis Inhibitors -- administration & dosage
- Bevacizumab -- administration & dosage
- Biomarkers -- blood
- Diabetic Retinopathy -- blood
- Dose-Response Relationship, Drug
- Eye Proteins -- blood
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Macular Edema -- blood
- Male
- Middle Aged
- Prospective Studies
- RNA, Messenger -- blood
- Ranibizumab -- administration & dosage
- Retina -- pathology
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.